Literature DB >> 29980011

Trigonelline inhibits intestinal microbial metabolism of choline and its associated cardiovascular risk.

Siraj Anwar1, Uma Bhandari2, Bibhu Prasad Panda3, Kiran Dubey1, Washim Khan4, Sayeed Ahmad4.   

Abstract

Gut microbiota based metabolism of choline produces trimethylamine (TMA) which is further converted to a pro-atherosclerotic metabolite, trimethylamine-N-oxide (TMAO) by flavin monooxygenase (FMO3). Trigonelline from the plant Trigonella foenum-graecum has been reported for the treatment of CVD. Aim of the present study was to check the effect of trigonelline on the gut microbiota based conversion of TMA to TMAO. Trigonelline was isolated from hydroalcoholic extract of seeds of Trigonella foenum-graecum. The isolated trigonelline was characterized through TLC and UPLC-MS. Anaerobic microbe responsible for the metabolism of choline to TMA was isolated by culturing the human gut microbiota in choline enriched medium. The isolated bacteria was identified at molecular level based on PCR amplification of 1500bp of 16S rRNA gene sequence. Isolated FMO3 was used for ex vivo conversion of TMA to TMAO. Further, we investigated the effect of trigonelline in isolated gut microbe based metabolism of choline, lipid profile and TMAO levels in mice with or without suppression of gut microbiota with antibiotics. Liquid-liquid purification and chromatographic analysis confirmed the trigonelline purity (87.26%) and which was also confirmed by mass spectroscopy with m/z 137.4 in positive ionization mode. A total of 30 anaerobic microbes responsible for TMA production were isolated and Citrobacter freundii was the superior among others for the production of TMA. In vitro culture of C. freundii in choline enriched medium supplemented with trigonelline resulted in significantly reduction TMA and followed by TMAO production. In ex vivo, a maximum of 85.3% TMAO production was reduced by trigonelline at concentration of about 300 μg/mL. Serum level of lipids and TMAO were significantly altered in choline fed animals with or without suppression of gut microbiota and this phenomenon was reversed upon the oral administration of trigonelline in a dose-dependent manner. This study demonstrates the effect of trigonelline on gut microbiota responsible for choline metabolism and this can be used as a model for evaluation of herbal drugs and its effect in gut microbiota prompted cardiovascular disorders.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Choline; Gut microbiota; In vivo; Trimethylamine-N-oxide; UPLC-MS

Mesh:

Substances:

Year:  2018        PMID: 29980011     DOI: 10.1016/j.jpba.2018.06.027

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  15 in total

1.  Discovery of a Cyclic Choline Analog That Inhibits Anaerobic Choline Metabolism by Human Gut Bacteria.

Authors:  Maud Bollenbach; Manuel Ortega; Marina Orman; Catherine L Drennan; Emily P Balskus
Journal:  ACS Med Chem Lett       Date:  2020-03-25       Impact factor: 4.345

Review 2.  Targeting Trimethylamine N-Oxide: A New Therapeutic Strategy for Alleviating Atherosclerosis.

Authors:  Lele Jing; Honghong Zhang; Qiannan Xiang; Liang Shen; Xiaoxia Guo; Changlin Zhai; Huilin Hu
Journal:  Front Cardiovasc Med       Date:  2022-06-13

Review 3.  The Role of Gut Microbiota and Trimethylamine N-oxide in Cardiovascular Diseases.

Authors:  Yan Huang; Han Zhang; Xin Fan; Junpeng Wang; Yuzhen Yin; Yu Zhang; Kuangyu Shi; Fei Yu
Journal:  J Cardiovasc Transl Res       Date:  2022-10-17       Impact factor: 3.216

Review 4.  Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota.

Authors:  Anna E Lindell; Maria Zimmermann-Kogadeeva; Kiran R Patil
Journal:  Nat Rev Microbiol       Date:  2022-01-31       Impact factor: 78.297

5.  Characteristic Analysis of Trigonelline Contained in Raphanus sativus Cv. Sakurajima Daikon and Results from the First Trial Examining Its Vasodilator Properties in Humans.

Authors:  Maho Sasaki; Yuri Nonoshita; Takashi Kajiya; Nobuhiko Atsuchi; Megumi Kido; Djong-Chi Chu; Lekh Raj Juneja; Yuji Minami; Katsuko Kajiya
Journal:  Nutrients       Date:  2020-06-23       Impact factor: 5.717

6.  Fecal Metabolomics and Potential Biomarkers for Systemic Lupus Erythematosus.

Authors:  Qiong Zhang; Xiaofeng Yin; Haifang Wang; Xing Wu; Xin Li; Yao Li; Xiaohe Zhang; Chen Fu; Haixia Li; Yurong Qiu
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

7.  UHPLC-Q-TOF/MS-Based Metabolomics Approach Reveals the Antifungal Potential of Pinocembroside against Citrus Green Mold Phytopathogen.

Authors:  Chuying Chen; Nan Cai; Jinyin Chen; Chunpeng Wan
Journal:  Plants (Basel)       Date:  2019-12-22

Review 8.  Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target.

Authors:  Shengjie Yang; Xinye Li; Fan Yang; Ran Zhao; Xiandu Pan; Jiaqi Liang; Li Tian; Xiaoya Li; Longtao Liu; Yanwei Xing; Min Wu
Journal:  Front Pharmacol       Date:  2019-11-19       Impact factor: 5.810

Review 9.  Trimethylamine N-Oxide Generated by the Gut Microbiota Is Associated with Vascular Inflammation: New Insights into Atherosclerosis.

Authors:  Yarong Liu; Min Dai
Journal:  Mediators Inflamm       Date:  2020-02-17       Impact factor: 4.711

10.  Untargeted fecal metabolome analysis in obese dogs after weight loss achieved by feeding a high-fiber-high-protein diet.

Authors:  Sandra Bermudez Sanchez; Rachel Pilla; Benjamin Sarawichitr; Alessandro Gramenzi; Fulvio Marsilio; Joerg M Steiner; Jonathan A Lidbury; Georgiana R T Woods; Jan S Suchodolski; Alexander J German
Journal:  Metabolomics       Date:  2021-07-06       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.